CIBC Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

CIBC Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$377K	Hold	5,017	–	–	﹤0.01%	886
2025 Q4	$397K	Buy	5,017 +409	+9%	+$30.8K	﹤0.01%	865
2025 Q3	$301K	Buy	+4,608	New	+$225K	﹤0.01%	934
2024 Q1	–	Sell	-4,002	Closed	-$202K	–	1139
2023 Q4	$202K	Buy	+4,002	New	+$192K	﹤0.01%	997
2022 Q4	–	Sell	-5,203	Closed	-$230K	–	1163
2022 Q3	$230K	Buy	+5,203	New	+$219K	﹤0.01%	1008
2022 Q2	–	Sell	-5,583	Closed	-$207K	–	1376
2022 Q1	$207K	Buy	+5,583	New	+$183K	﹤0.01%	1363
2021 Q3	–	Sell	-5,140	Closed	-$205K	–	1477
2021 Q2	$205K	Hold	5,140	–	–	﹤0.01%	1275
2021 Q1	$231K	Sell	5,140 -106	-2%	-$5.91K	﹤0.01%	1141
2020 Q4	$297K	Hold	5,246	–	–	﹤0.01%	906
2020 Q3	$249K	Buy	5,246 +130	+3%	+$7.22K	﹤0.01%	909
2020 Q2	$302K	Hold	5,116	–	–	﹤0.01%	799
2020 Q1	$242K	Hold	5,116	–	–	﹤0.01%	801
2019 Q4	$309K	Buy	5,116 +613	+14%	+$36.5K	﹤0.01%	867
2019 Q3	$270K	Hold	4,503	–	–	﹤0.01%	885
2019 Q2	$289K	Hold	4,503	–	–	﹤0.01%	871
2019 Q1	$366K	Hold	4,503	–	–	﹤0.01%	785
2018 Q4	$243K	Hold	4,503	–	–	﹤0.01%	856
2018 Q3	$232K	Buy	+4,503	New	+$212K	﹤0.01%	980
2018 Q1	–	Sell	-4,190	Closed	-$211K	–	1073
2017 Q4	$211K	Hold	4,190	–	–	﹤0.01%	986
2017 Q3	$212K	Buy	+4,190	New	+$219K	﹤0.01%	939
2016 Q1	–	Sell	-3,637	Closed	-$225K	–	955
2015 Q4	$225K	Buy	+3,637	New	+$196K	﹤0.01%	823
2015 Q3	–	Sell	-3,637	Closed	-$209K	–	956
2015 Q2	$209K	Buy	3,637 +117	+3%	+$7.44K	﹤0.01%	898
2015 Q1	$224K	Buy	3,520 +210	+6%	+$14.2K	﹤0.01%	870
2014 Q4	$204K	Buy	+3,310	New	+$163K	﹤0.01%	879

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIBC Asset Management's IONS Position: Q1 2026 in Review

CIBC Asset Management held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 5,017 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #886.

CIBC Asset Management first reported a position in IONS in Q4 2014 and has held it in 24 quarters since. The position peaked at $397K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

CIBC Asset Management held 5,017 shares of Ionis Pharmaceuticals worth $377K as of Q1 2026.
CIBC Asset Management left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
Ionis Pharmaceuticals made up ﹤0.01% of CIBC Asset Management's portfolio in Q1 2026, its #886 holding.
CIBC Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2014 and has held it in 24 quarters since.
CIBC Asset Management's Ionis Pharmaceuticals position peaked at $397K in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on CIBC Asset Management's 13F filing for Q1 2026, filed 12 May 2026.